Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
1 May 2012 |
Main ID: |
EUCTR2009-010065-23-DE |
Date of registration:
|
14/04/2009 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Conventional Step-Up versus Infliximab Monotherapy in Patients with Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study (Phase 3, Protocol No. P05553) - MUNIX
|
Scientific title:
|
Conventional Step-Up versus Infliximab Monotherapy in Patients with Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study (Phase 3, Protocol No. P05553) - MUNIX |
Date of first enrolment:
|
17/08/2009 |
Target sample size:
|
|
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-010065-23 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: yes
Other specify the comparator: therapy design
|
Phase:
|
|
|
Countries of recruitment
|
Germany
| | | | | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Adult (=18 years) men and women with diagnosis of active UC for at least 3 months' duration (Mayo score of 6 to 12 points, inclusive) at the screening visit. 2. A previous diagnosis of UC must have been confirmed by colonoscopy and biopsy. 3. Inadequate response to oral (with or without topical) 5-ASA treatment and considered for the first course of systemic corticosteroids. 4. Screening visit colonoscopy with biopsies must be performed within 2 weeks prior to the baseline. At least 72 hours must elapse between a colonoscopy with polypectomy or multiple biopsies and the baseline (week 0) visit. 5. Evidence of active disease beyond the rectum and including more than 20 cm of the colon during the screening visit colonoscopy (Mayo score of = 2 on the endoscopy subscore of the Mayo score). 6. Each subject must be negative for colorectal cancer or any associated lesions (e.g. hyperplasia). 7. Each subject must have negative tuberculosis screening results. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria: 1. Previous treatment for UC with systemic corticosteroids, infliximab, AZA/6-MP, cyclosporine, tacrolimus, methotrexate, sirolimus, mycophenolate, any TNFa inhibitor or receptor constructs that bind to ??Fa (e.g., etanercept or adalimumab) and any other biologic agents. 2. Severe extensive colitis as evidenced by: a. Investigator judgment that the subject is likely to require colectomy within 12 weeks of the baseline visitOR b. Symptom complex at the screening or baseline visits, including at least four of the following: • Diarrhea with = 6 bowel movements/day with macroscopic blood in stool, • Focal severe or rebound abdominal tenderness, • Persistent fever (= 37.5°C) • Tachycardia (> 90 beats/minute) • Anemia (Hb< 8.5 g/dL). 3. Within the 2 months prior to and including the screening visit: Requirement for surgery for active gastrointestinal bleeding, peritonitis, intestinal obstruction, or intra-abdominal or pancreatic abscess requiring surgical drainage or other conditions possibly confounding the evaluation of benefit from infliximab treatment. 4. Presence of adenomatous polyps.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Active Moderate to Severe Ulcerative Colitis MedDRA version: 14.1
Level: LLT
Classification code 10066678
Term: Acute ulcerative colitis
System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 14.1
Level: LLT
Classification code 10033007
Term: Other ulcerative colitis
System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 14.1
Level: LLT
Classification code 10045366
Term: Ulcerative colitis, unspecified
System Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 14.1
Level: LLT
Classification code 10045365
Term: Ulcerative colitis
System Organ Class: 10017947 - Gastrointestinal disorders
|
Intervention(s)
|
Trade Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: infliximab Other descriptive name: 100 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-
Trade Name: Pentasa 500 mg Retardtabletten Product Name: 5-Aminosalicylic acid (5-ASA) Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: 5-Aminosalicylic acid Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-
Trade Name: Imurek 25mg Filmtabletten Pharmaceutical Form: Coated tablet INN or Proposed INN: azathioprine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25-
Trade Name: Imurek 50mg Filmtabletten Pharmaceutical Form: Coated tablet INN or Proposed INN: azathioprine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-
Trade Name: Decortin H 1 mg Pharmaceutical Form: Tablet INN or Proposed INN: prednisolone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-
Trade Name: Decortin H 5mg Pharmaceutical Form: Tablet INN or Proposed INN: prednisolone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5-
Trade Name: Decortin H 10mg Pharmaceutical Form: Tablet INN or Proposed INN: prednisolone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-
Trade Name: Decortin H 20mg Pharmaceutical Form: Tablet INN or Proposed INN: prednisolone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20-
Trade Name: Decortin H 50 mg Pharmaceutical Form: Tablet INN or Proposed INN: prednisolone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-
|
Primary Outcome(s)
|
Secondary Objective: Comparison of the two treatment groups with regard to: • Proportion of subjects with response at week 4 • Proportion of subjects in remission at week 50 • Proportion of subjects off steroids at week 50 • Corticosteroid use over the trial duration • Proportion of subjects in remission and off steroids and with no surgery at week 50 • Mucosal healing at week 50 • Clinical assessment of disease activity (Mayo score) • QoL as measured by IBDQ • Proportion of subjects with hospitalizations • Proportion of subjects with colectomy during the study • Proportion of subjects with Level 3 treatment1 • Number of flares and time to flare • Safety profile
|
Main Objective: The primary objective of the study is to show superiority of infliximab monotherapy (Top-Hold regimen) versus the classical Step-Up therapy with respect to the proportion of subjects with moderate to severe active UC who achieve response within 4 weeks after starting treatment and steroid free remission at week 50.
|
Primary end point(s): The primary efficacy endpoint for this trial is the proportion of subjects with moderate to severe active UC who achieve response within 4 weeks after starting treatment and steroid free remission at week 50.
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|